Varda Space Industries, a space startup focused on manufacturing drugs in orbit, has secured $187 million in a Series C funding round. The round was led by venture capital firms Natural Capital and Shrug Capital. The funding aims to advance Varda's technology for robotic drug manufacturing in space, expanding its ambitions beyond initial successes. The company envisions establishing large-scale laboratories in orbit, which it describes as potentially visible from Earth. This investment reflects growing interest from leading Silicon Valley players in the potential of space-based pharmaceutical production. Separately, data center infrastructure automation startup Spacelift raised $51 million to support its growth.